 |
|
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
Tarun Kadaru, Amal Shibli-Rahhal
J Bone Metab. 2021;28(1):51-58. Published online 2021 Feb 28 DOI: https://doi.org/10.11005/jbm.2021.28.1.51
|
|
Citations to this article as recorded by
 Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
Ta-Wei Tai, Hsuan-Yu Chen, Chien-An Shih, Chun-Feng Huang, Eugene McCloskey, Joon-Kiong Lee, Swan Sim Yeap, Ching-Lung Cheung, Natthinee Charatcharoenwitthaya, Unnop Jaisamrarn, Vilai Kuptniratsaikul, Rong-Sen Yang, Sung-Yen Lin, Akira Taguchi, Satoshi Mo
Osteoporosis and Sarcopenia.2024; 10(1): 3. CrossRef A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Zhanna Belaya, Liudmila Rozhinskaya, Ivan Dedov, Oksana Drapkina, Valentin Fadeev, Olga Golounina, Olga Lesnyak, Elizaveta Mamedova, Galina Melnichenko, Alexey Petraikin, Svetlana Rodionova, Irina Skripnikova, Olga Tkacheva, Natalia Toroptsova, Svetlana Y
Osteoporosis International.2023; 34(3): 429. CrossRef Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Christian Horst Tonk, Sarah Hani Shoushrah, Patrick Babczyk, Basma El Khaldi-Hansen, Margit Schulze, Monika Herten, Edda Tobiasch
International Journal of Molecular Sciences.2022; 23(3): 1393. CrossRef Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis
Namki Hong, Sungjae Shin, Seunghyun Lee, Kyoung Jin Kim, Yumie Rhee
Calcified Tissue International.2022; 111(1): 47. CrossRef Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
Jung-Wee Park
Journal of Bone Metabolism.2021; 28(4): 339. CrossRef
|